FTRP – Field Trip Health Ltd

Field Trip Health Ltd. is engaged in the development and delivery of psychedelic-assisted therapies (PAT). Through its Field Trip Discovery, it is engaged in developing psychedelic molecules and conducts research on plant-based psychedelics. Its Field Trip Health division operates clinics across North America and Europe providing ketamine-assisted psychotherapy (KAP) and therapies with other legal psychedelics under various programs. Its Field Trip Discovery division focuses on developing medicines targeting serotonin 5HT2A receptors. It is conducting preclinical research into its first psychedelic molecule, FT-104, targeted for treatment resistant depression (TRD) and postpartum depression (PPD). It is also exploring families of new chemical entity (NCE) structures, coined the FT-200 Group. Its Field Trip Digital division develops digital tools, such as the mobile application, Trip, and the patient application, Portal, to support and enhance patient outcomes and experience.